«78910111213›»Seite
13 Artikel mit Literatur, Seite 13 von 13

MEDIZIN: cme

Therapie von Beschwerden in den Wechseljahren

The Treatment of Climacteric Symptoms
Dtsch Arztebl Int 2012; 109(17): 316-24; DOI: 10.3238/arztebl.2012.0316

Ortmann, Olaf; Lattrich, Claus

1. Ortmann O, Dören M, Windler E: Hormone therapy in perimenopause and postmenopause (HT): Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 2011; 284: 343–55 CrossRef PubMed Central MEDLINE
2. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: S3-Leitlinie Hormontherapie in der Peri- und Postmenopause “.
3. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR: Duration of menopausal hot flushes and associated risk factors. Obstetrics and gynecology 2011; 117: 1095–104 CrossRef
4. Arneimittelkommission der deutschen Ärzteschaft: Hormontherapie im Klimakterium
5. New Zealand Guidelines Group. The appropriate prescribing of hormone replacement therapy. Bestpractice evidence-based guideline, Wellington: New Zealand Guidelines Group 2001.
6.Utian WH, Archer DF, Bachmann GA, et al.: Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15(4 Pt 1): 584–602.
7.Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane database of systematic reviews 2004; (4): CD002978.
8. Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD: Influence of menopause on mood: a systematic review of cohort studies. Climacteric : the journal of the International Menopause Society 2007; 10: 448–65.
9. Nelson HD, Vesco KK, Haney E, et al.: Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA: the journal of the American Medical Association 2006; 295: 2057–71. CrossRef MEDLINE
10. Fotherby K: Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 1996; 54: 59–69 CrossRef
11. NAMS: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242–55 CrossRef
12. Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane database of systematic reviews 2003; (4): CD001500 MEDLINEMEDLINE
13. Moehrer B, Hextall A, Jackson S: Oestrogens for urinary incontinence in women. Cochrane database of systematic reviews 2003; (2): CD001405 MEDLINE MEDLINE
14. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T: Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics and gynecology 2001; 97: 116–20 CrossRef
15. Barnabei VM, Cochrane BB, Aragaki AK, et al.: Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstetrics and gynecology 2005; 105
(5 Pt 1): 1063–73 CrossRef
16. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane database of systematic reviews 2008; 2: CD005131 MEDLINE
17. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891–7 CrossRef
18. Wells G, Tugwell P, Shea B, et al.: Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529–39 CrossRef MEDLINE
19. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA: Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane database of systematic reviews 2005; (3): CD004143 MEDLINE
20. Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12 CrossRefMEDLINE
21. LaCroix AZ, Chlebowski RT, Manson JE, et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305–14 CrossRef MEDLINE
22. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O: Hormone therapy and ovarian cancer. JAMA 2009; 302: 298–305 CrossRef MEDLINE
23. Grodstein F, Newcomb PA, Stampfer MJ: Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. AmJ Med 1999; 106: 574–82 CrossRef
24. Tsilidis KK, Allen NE, Key TJ, et al.: Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128: 1881–9 CrossRef
e1. Ortmann O: Hormontherapie in der Peri- und Postmenopause. Frauenarzt 2009; 50: 840–51.
e2. NAMS: Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–82 MEDLINE
e3. Eberhardt S, Kulp W, von der Schulenburg JM, Willich SN, Keil T, Greiner W: Hormones for therapy of climacteric afflictions. GMS health technology assessment 2007; 3: Doc03.
e4.The North American Menopause Society: Menopause Practice: A Clinician’s Guide, 4th edition.
e5. Rigg LA, Hermann H, Yen SS: Absorption of estrogens from vaginal creams. The New England journal of medicine 1978; 298: 195–7 MEDLINE
e6. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L: Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstetrics and gynecology 1998; 92(4 Pt 2): 722–7 MEDLINE
e7. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14(3 Pt 1): 355–69; quiz 370–1 MEDLINE
e8. Dannecker C, Friese K, Stief C, Bauer R: Urinary incontinence in women: part 1 of a series of articles on incontinence. Deutsches Arzteblatt international 2010; 107: 420–6 MEDLINE PubMed Central
e9. MacLean C, Newberry S, Maglione M, et al.: Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of internal medicine 2008; 148: 197–213 MEDLINE
e10. Deutsche Gesellschaft für Osteologie e.V. (DGO): S3 Leitlinie „Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr “.
e11. Prentice R, Manson J, Langer R, et al.: Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170: 12–23 MEDLINE PubMed Central
e12. Shah NR, Borenstein J, Dubois RW: Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005; 12: 668–78 CrossRefPubMed Central
e13. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D: Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics and gynecology 1995; 85: 304–13 MEDLINE
e14. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer 2007; 91: 1–528.
e15. Zhou B, Sun Q, Cong R, et al.: Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008; 108: 641–51 MEDLINE
«78910111213›»Seite
13 Artikel mit Literatur, Seite 13 von 13

Login

E-Mail

Passwort


Passwort vergessen?

Registrieren

Eingeloggt als

Suchen in